April 9, 2019 - Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a US subsidiary of Hitachi Chemical Co. Ltd. that engages in contract manufacturing and development of cell therapy products, and Saint-Gobain, a global leader in single-use solutions for the Biopharmaceutical industry, today announced a joint development agreement to co-develop and commercialize novel technology solutions, specifically for the cell therapy industry. This collaboration will allow both parties to leverage their decades of experience and unique capabilities to address manufacturing needs of cell therapy product developers and challenges such as CAR-T genetic modification and culture and closed in-process product sampling.
“With hundreds of cell therapy clinical trials underway and being planned, the industry continues to be faced with challenges to properly prepare for sustainable commercialization of these promising therapies,” said Robert A. Preti, Ph.D., CEO and President of HCATS and General Manager of the Hitachi Chemical Regenerative Medicine Business Sector. “We are excited to partner with Saint-Gobain and look forward to supporting this growing industry by addressing our customers’ unique manufacturing challenges.”
“The collaboration between our two organizations provides an exciting opportunity to develop solutions to address the unique challenges associated with large scale production of patient specific therapies,” said Benjamin Le Quere, General Manager for the Saint-Gobain Bioprocess Solutions business unit. “We are confident that together, HCATS and Saint-Gobain can create innovative, scalable production processes for this industry.”
About Hitachi Chemical Advanced Therapeutics Solutions
Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS, formerly PCT Cell Therapy Services, LLC), is a wholly owned subsidiary of Hitachi Chemical Company, Ltd. (Hitachi Chemical) representing Hitachi Chemical’s Regenerative Medicine Business Sector in the United States. HCATS leverages two decades of experience exclusively focused on the cell therapy industry. It provides contract development and manufacturing organization (CDMO) services at current Good Manufacturing Practices (cGMP) standards, including clinical manufacturing, commercial manufacturing, and manufacturing development. Facilities to deliver these services under a global harmonized service platform have been established in Japan (Yokohama City, Kanagawa Prefecture), and in the United States (New Jersey and California), with an expansion to add commercial manufacturing capabilities and capacity underway in New Jersey. For more information about these services, please visit www.pctcelltherapy.com
For more information, contact:
Hitachi Chemical Advanced Therapeutics Solutions, LLC
Tel: +1 201 515 2153
About Saint-Gobain Life Sciences
Dedicated to improving the quality of life, Saint-Gobain Life Sciences develops and manufactures high-performance components and integrated solutions that touch a broad range of patient care, from the development of new therapeutic cancer treatments to biopharmaceutical production, on through to intravenous therapies for drug delivery.
Along with material science expertise and collaborative design services, our focus on global quality and regulatory affairs allow us to be the trusted partner to organizations reaching every part of the globe. Combining our technical expertise, global manufacturing capabilities and research and development resources, Saint-Gobain Life Sciences is dedicated to meeting the evolving needs of bioprocess, medical and pharmaceutical customers around the world.
For more information, contact:
Saint-Gobain Life Sciences
Product Manager – Cell Therapy
Tel: +1 989 424 8968